Inhibition of AQP1 Hampers Osteosarcoma and Hepatocellular Carcinoma Progression Mediated by Bone Marrow-Derived Mesenchymal Stem Cells

Alessandra Pelagalli 1,2,*, Anna Nardelli 2, Raffaela Fontanella 2 and Antonella Zannetti 2,*

1 Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli “Federico II”, Via Pansini No. 5, 80131 Napoli, Italy
2 Istituto di Biostrutture e Bioimmagini-CNR, Via De Amicis No. 95, 80145 Napoli, Italy; anna.nardelli@ibb.cnr.it (A.N.); raffaela.fontanella@alice.it (R.F.)
* Correspondence: alpelaga@unina.it (A.P.); antonella.zannetti@cnr.it (A.Z.); Tel.: +39-081-220-3431 (A.Z.)

Abstract: The complex cross-talk between tumor cells and their surrounding stromal environment plays a key role in the pathogenesis of cancer. Among several cell types that constitute the tumor stroma, bone marrow-derived mesenchymal stem cells (BM-MSCs) selectively migrate toward the tumor microenvironment and contribute to the active formation of tumor-associated stroma. Therefore, here we elucidate the involvement of BM-MSCs to promote osteosarcoma (OS) and hepatocellular carcinoma (HCC) cells migration and invasion and deepening the role of specific pathways. We analyzed the function of aquaporin 1 (AQP1), a water channel known to promote metastasis and neoangiogenesis. AQP1 protein levels were analyzed in OS (U2OS) and HCC (SNU-398) cells exposed to conditioned medium from BM-MSCs. Tumor cell migration and invasion in response to BM-MSC conditioned medium were evaluated through a wound healing assay and Boyden chamber, respectively. The results showed that the AQP1 level was increased in both tumor cell lines after treatment with BM-MSC conditioned medium. Moreover, BM-MSCs-mediated tumor cell migration and invasion were hampered after treatment with AQP1 inhibitor. These data suggest that the recruitment of human BM-MSCs into the tumor microenvironment might cause OS and HCC cell migration and invasion through involvement of AQP1.

Keywords: BM-MSCs; osteosarcoma; hepatocellular carcinoma; AQP1; migration; invasion

1. Introduction

Tumors are essentially composed of two interdependent compartments, namely tumor cells and surrounding stroma. Tumor stroma is largely a product of the host and contains connective tissue, blood vessels and several types of resident and infiltrating host cells. The most apparent function of tumor stroma is to provide a structural support to tumor cells but it has become increasingly evident that it also interacts with tumor cells and evolves with them [1]. In fact, the architecture surrounding the tumor is not static but is subjected to a continuous remodelling in response to the dynamic interplay between tumor cells and stroma [2]. While tumor cells have a clonal origin and grow accumulating mutations in different genes, stromal cells are non malignant, polyclonal and have variable origin. In tumor microenvironment (TME) there are many stromal cells including: fibroblasts, endothelial cells of the blood and lymphatic circulation, pericytes and a variety of bone marrow-derived cells that comprise macrophages, neutrophils, mast cells, myeloid-derived suppressor cells and mesenchymal stem cells (Figure 1). Specific homing to TME of bone marrow mesenchymal stem cells (BM-MSCs) and their immunosuppressive effect renders them appropriate vehicles to deliver drugs to TME [3].
Conversely, it has been demonstrated that BM-MSCs contribute to the development of cancer stem cell (CSC) niche in breast [4] and prostate carcinomas [5].

![Diagram](Int J Mol Sci. 2016, 17, 1102)

**Figure 1.** The primary tumor microenvironment. Cancer cells in primary tumor are surrounded by a complex microenvironment including multiple stromal cell types that converge to promote tumor growth and dormancy, invasion and metastasis development and resistance to therapy. Key role of bone-marrow derived mesenchymal stem cells (BM-MSCs) in tumor cell migration and invasion. Cancer stem cell (CSC); carcinoma associated fibroblasts (CAFs); dendritic cell (DC); myeloid-derived-suppressor cells (MDSCs); natural killer (NK); tumor associated macrophages (TAM).

There is no doubt that bidirectional communication between cancer cells and surrounding stroma can promote the transfer of information for as the production of factors (growth factors, cytokines and chemokines) acting through a paracrine mechanism to modify the microenvironment. Moreover, it has demonstrated that tumor cells secrete extracellular vesicles containing different biomolecules (proteins, RNA, DNA and lipids) [6] that may be involved in promoting cancer progression and may represent targets for therapeutic intervention [7]. Such modifications in the microenvironment can stimulate tumor initiation, proliferation and metastasis. In the last decades, many studies focused attention on the possible involvement of aquaporins (AQPs), a family of proteins characterized for their particular ability to regulate water and solute trafficking along membrane, with tumor progression [8]. Recent findings demonstrated that water homeostasis regulated by aquaporins represents an important mechanism at the basis of numerous processes such as cancer cell differentiation [9,10] and proliferation as well as apoptosis [11]. Moreover, aquaporins seem to be involved in tumor cell migration [12] and thus, in tumor spread and metastasis because of their sensitivity to changes in extracellular osmolality [13]. In particular, many studies showed a key role of AQP1 in metastatic process and neo-angiogenesis in a tumor animal model [14]. Nude mice that received AQP1-expressing melanoma cells via the tail vein developed more lung metastases at 3 weeks with respect to control mice [15]. AQP1 is strongly expressed in several human breast carcinomas, glioblastoma multiformes and several types of primary lung tumors. Moreover, it has been well demonstrated that tumors expressing AQP1 were more infiltrative compared with AQP1-null tumors [12]. Recent studies reported that AQPs might play an important role in human hepatocarcinoma cells (HCCs) [16]. Furthermore, Wu et al. (2015) [17] found that AQP1 mRNA was elevated in osteosarcoma tissue and a high level of
AQP1 was associated with poor prognosis in osteosarcoma. In this study, we analyzed the involvement of AQP1 in osteosarcoma (OS) and hepatocellular carcinoma (HCC) progression due to BM-MSCs.

2. Results

2.1. Enhancement of Aquaporin 1 (AQP1) Levels in Osteosarcoma (OS) and Hepatocellular Carcinoma (HCC) Cells by Conditioned Medium from Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)

We evaluated whether conditioned medium from BM-MSCs (BM-MSC-CM) could affect the expression of the water channel AQP1 in osteosarcoma cells (U2OS) and hepatocellular carcinoma cells (SNU-398). BM-MSC-CM treatment of OS and HCC cells for 24 h caused a significant increase in AQP1 protein levels (Figure 2A). We found that BM-MSCs induced a 25- and 2.3-fold enhancement in AQP1 levels in U2OS and SNU-398 cells, respectively, with respect to the control (10% fetal bovine serum (FBS)) (Figure 2B).

![Figure 2](image-url). Conditioned medium (CM) from bone-marrow-derived mesenchymal stem cells (BM-MSC) increases aquaporin 1 (AQP1) levels in SNU-398 and osteosarcoma cells (U2OS) tumor cell lines. (A) Western blot analysis of AQP1 expression in U2OS and SNU-398 after treatment with BM-MSC-CM for 24 h. The equal protein loading was evaluated by using actin. Representative images from three independent studies; (B) AQP1 levels were represented as fold change respect to 10% fetal bovine serum (FBS), which was arbitrarily determined to be 1. Results are expressed as means ± SD.

2.2. Inhibition of AQP1 Hampers OS and HCC Cell Migration Bone Marrow-Derived Mesenchymal Stem Cells-Conditioned Medium (BM-MSC-CM)-Mediated

Because tumor cells with high levels of AQP1 had a stronger capacity for cell migration, invasion, and metastasis [15], the BM-MSC-CM effect on wound healing was investigated. After wounding, images of U2OS and SNU-398 migration were acquired at 0 and 24 h (Figure 3A,B). The treatment with BM-MSC-CM induced a significant wound closure enhancement in U2OS cells (49.6%) with respect to control cells (1% FBS) \((p < 0.01)\). Treatment with 100 µM of the AQP1 inhibitor [18] tetraethylammonium chloride (TEA) in U2OS cells cultured in the presence of BM-MSC-CM caused a significant delay in wound closure (16.6%) with respect to cells grown in the presence of BM-MSC-CM alone \((p < 0.001)\).
Similar to that shown in U2OS cells, BM-MSC-CM induced significant wound closure enhancement (44.5%) in SNU-398 cells. Similar to OS cells, TEA induced a significant reduction of BM-MSC-CM-mediated wound closure (13%) in HCC cells ($p < 0.001$) (Figure 3B).

2.3. Inhibition of AQP1 Hampers BM-MSCs-CM-Dependent OS and HCC Cell Invasion

To assess the BM-MSC effect on U2OS and SNU-398 cell invasiveness, a Boyden chamber with membrane pre-coated with matrigel was used. A significant increase in OS and HCC cell invasiveness with respect to the control (1% FBS supplemented medium) was observed when both tumor cell lines were seeded in the upper chamber and exposed for 48 h to BM-MSC-CM as chemoattractant (lower chamber). The AQP1 inhibitor (TEA) caused a significant decrease in the BM-MSC-mediated U2OS and SNU-398 cell invasion rate ($p < 0.001$) (Figure 4A, B).
were seeded in the upper chamber and exposed for 48 h to BM-MSC-CM as chemoattractant (lower chamber). The AQP1 inhibitor (TEA) caused a significant decrease in the BM-MSC-mediated U2OS and SNU-398 cell invasion rate ($p < 0.001$) (Figure 4A,B).

![Figure 4](image-url)

Figure 4. AQP1 inhibitor prevented BM-MSC-CM-mediated invasion of U2OS and SNU-398 cells. (A,B) Invasion assay was performed using a Boyden chamber pre-coated with matrigel. Tumor cells were seeded in the upper chamber whereas 1% FBS (negative control), 10% FBS (positive control) and BM-MSC-CM were added to the lower chamber as chemoattractants. Tumor cells were treated or not treated with AQP1 inhibitor TEA (100 µM). Results are expressed as means ± SD. * $p < 0.001$ and # $p < 0.001$. Scale bar = 600 µm.

3. Discussion

As in normal wound healing, tumors also activate the recruitment of host cells into the tumor microenvironment to regulate survival and proliferation [19]. Recently, bone marrow mesenchymal stem cells were shown to be recruited into primary tumor sites and contribute to the development of niches for cancer stem cells and the epithelial-to-mesenchymal transition (EMT) program [20]. In particular, growing evidence supports the hypothesis that BM-MSCs participate in TME differentiation into carcinoma-associated fibroblasts (CAFs) [21,22]. Many studies reported that BM-MSCs promote tumor proliferation and invasion of different carcinomas including breast [4,23], prostate [20,22], osteosarcoma [24–26] and colon [27–29]. Recent studies have also clarified the role of tumor cells as
cells capable of modifying their environment by releasing important biomolecules from extracellular vesicles [7]. Furthermore, proteins, RNA and lipids released by tumor cells may be clinically relevant to cancer progression and useful in diagnosis of cancer and assessment of prognosis. Previous work by our group demonstrated that BM-MSCs induce OS and HCC progression through CXCR4 activation [30]. Furthermore, we observed an inhibition of the EMT program when OS and HCC cells were treated with a novel CXCR4 antagonist. It has been observed that through enhanced water flux mediated by the AQP channels, tumor cells are believed to acquire an enhanced migratory and invasive phenotype [12]. AQP1 is up-regulated in different carcinomas including: colon, breast, lung and glioblastoma multiforme [15]. Several reports found that AQP1 overexpression in tumor cells may increase tumor invasiveness and angiogenesis [31].

In the present study, we used tetraethylammonium (TEA) to block AQP1. The inhibitor effect of this molecule on AQP1 function is controversial. Brooks et al. [18], for the first time, reported that TEA reduced the water permeability of human AQP1 expressed in Xenopus oocytes. These data were subsequently confirmed and a much stronger AQP1 inhibition by TEA was observed [32]. Moreover, a combination of three different theoretical approaches identified the binding site for TEA in human AQP1, thus suggesting this compound as a putative lead for AQP1 selective blockers [33]. Conversely, other studies did not support the action of this molecule to inhibit AQP1 activity [34,35]. The different behavior shown by TEA to block AQP1 could be dependent on the assay system used and the cell line tested [36].

In addition, Wu et al. [17] reported that knockdown of AQP1 by siRNA in osteosarcoma cells; U2OS or MG63 cells inhibited cell proliferation and significantly inhibited cell adhesion and invasion. Furthermore, the AQP1 inhibitor AqB013 abrogated migration and invasiveness of colon cancer cells and prevented endothelial tube formation in vitro [37]. In the present study, we demonstrate that BM-MSCs-CM stimulated migration and invasion of osteosarcoma and hepatocellular carcinoma cells and their effects were hampered by the addition of the AQP1 inhibitor, thus confirming the involvement of this channel protein in the first step of the metastatic process.

4. Materials and Methods

4.1. Cell Lines and Culture Conditions

The human osteosarcoma cells (U2OS) from Sigma-Aldrich (St. Louis, MO, USA) were grown in McCoy’s 5A. Hepatocellular carcinoma cells (SNU-398) from the American Type Culture Collection (Rockville, MD, USA), were cultured in DMEM. FBS (10%), penicillin (100 U/mL) and streptomycin (100 µg/mL) were added to both media. All cell lines were cultured in an incubator (37 °C; CO₂ 5%).

4.2. Bone Marrow Mesenchymal Stem Cell Isolation and Characterization (BM-MSCs)

BM-MSCs kindly provided by the Rizzoli Orthopaedic Institute were cultured in α-modification of minimal essential medium (α-MEM, Gibco, BRL, Gaithersburg, MD, USA) supplemented with 20% FCS for 2–3 passages [38]. Moreover, flow cytofluorimetric analysis was used to evaluate stemness in BM-MSCs markers (positive markers: CD44, CD73, CD90, CD105, CD146) (negative markers: CD34 and CD45).

In order to obtain conditioned medium (CM), BM-MSCs were seeded and grown in medium with 20% FCS until 70% cell confluence and then it was replaced with FCS-free medium for 24 h.

4.3. Western Blot Analysis

Cell lysates were lysed in 40 mM Hepes pH 7.5, 120 mM NaCl, 5 mM MgCl₂, 1 mM EGTA, 0.5 mM EDTA, 1% Triton X-100 containing protease (Complete Tablets-EDTA free, Roche, Basel, Switzerland) and phosphatase inhibitors (20 mM α-glycerol-3-phosphate, 2.5 mM Na-pyrophosphate) according to the method previously described [39]. After homogenization and centrifugation for 15 min at 13,000× g at 4 °C the protein suspension was collected and the protein content was determined using
a BCA protein assay kit (Thermo, Waltham, MA, USA). Equal proteins samples (50 µg) were loaded and separated by SDS-PAGE under reducing conditions. The next step was to transfer the separated proteins to PVDF membranes. After blocking in 5% milk, primary antibodies were added. After being washed in TTBS buffer, the membranes were incubated with horseradish peroxidase-labeled antimouse or antirabbit Ig antibodies for 1 h and then protein detection was performed by ECL system (Menlo Park, CA, USA). Each band of western blot was quantified by densitometric analysis using Image J. Anti-AQP1 (sc-20810, Santa Cruz, CA, USA) and anti-β-actin (A4700, Sigma-Aldrich) were used in the experiment.

4.4. Wound Healing Assay

U2OS or SNU-398 cells were plated in 6-well plates and grown until confluence. Then, a linear wound was gently created in the monolayer using a sterile yellow pipette tip. After rinsing with PBS to remove the debris, the cells were incubated with culture medium containing 1% FBS, 10% FBS, BM-MSCs-CM, or TEA (100 µM) at 37 °C and 5% CO₂ for 24 h. Images of wounds area were obtained using phase contrast microscopy. As the cell migrated to fill the scratched area, images were captured by a digital camera attached to microscope. The wound closure was quantitated in each sample as the area covered by the cells in 24 h using TScratch analysis software [40].

4.5. Cell Invasion Assay

24-well trans-well plates (with 8 µm pores membranes) (Corning Inc., Corning, NY, USA) were used. Membranes were pre-coated with diluted Matrigel (1:3 in PBS); U2OS and SNU-398 cells (2.5 × 10⁵) in serum-free medium were then plated in the upper chamber. In the lower chamber, the following were added as chemoattractants: medium containing 1% FBS, 10% FBS and conditioned medium obtained from BM-MSC. After 48 h incubation, the cells that had invaded the lower chamber were stained with 0.1% crystal violet, then colorant was eluted and the absorbance read at 570 nm. To block AQP1, U2OS and SNU-398 cells cells were treated with 100 µM of TEA, a specific AQP1 inhibitor.

4.6. Statistics

All experiments were independently performed at least three times and the data values are presented as means ± standard deviation (SD). Statistical analysis was performed by Student’s t test using GraphPad Instat (La Jolla, CA, USA). p ≤ 0.05 was considered statistically significant.

5. Conclusions

We found that AQP1 levels in osteosarcoma (OS) and hepatocellular carcinoma (HCC) cells were increased when tumor cells interacted with BM-MSCs in the microenvironment. In addition, we elucidated the key role of AQP1 in BM-MSC-induced migration and invasion of OS and HCC cells. In conclusion, our study may provide a potential therapeutic strategy targeting AQP1 to hamper cross-talk between BM-MSCs and tumor cells, thus preventing the establishment of distant metastasis.

Author Contributions: Alessandra Pelagalli and Antonella Zannetti conceived and designed the study. Alessandra Pelagalli, Anna Nardelli and Raffaela Fontanella performed the experiments. Alessandra Pelagalli and Antonella Zannetti wrote the paper. All authors read and approved the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

- **AQP**s: aquaporins
- α-MEM: α-modification of minimal essential medium
- BM-MSCs: bone marrow-derived mesenchymal stem cells
- CAFs: carcinoma associated fibroblasts
- CM: conditioned medium
- CSCs: cancer stem cells
DC dendritic cell
DMEM Dulbecco’s modified Eagle medium
ECL enhanced chemiluminescence
EMT epithelial-to-mesenchymal transition
FBS fetal bovine serum
FCS fetal calf serum
HCC hepatocellular carcinoma
MDSCs myeloid-derived-suppressor cells
NK natural killer
OS osteosarcoma
PBS phosphate buffered saline
SD standard deviation
TAM tumor associated macrophages
TEA tetraethylammonium chloride
TME tumor microenvironment

References
1. Quail, D.F.; Joyce, J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19, 1423–1437. [CrossRef] [PubMed]
2. Mueller, M.M.; Fusenig, N.E. Friends or foes—Bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4, 839–849. [CrossRef] [PubMed]
3. Khakoo, A.Y.; Pati, S.; Anderson, S.A.; Reid, W.; Elshal, M.F.; Rovira, I.I.; Nguyen, A.T.; Malide, D.; Combs, C.A.; Hall, G.; et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J. Exp. Med. 2006, 203, 1235–1247. [CrossRef] [PubMed]
4. Liu, S.; Ginestier, C.; Ou, S.J.; Clouthier, S.G.; Patel, S.H.; Monville, F.; Korkaya, H.; Heath, A.; Dutcher, J.; Kleer, C.G.; et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011, 71, 614–624. [CrossRef] [PubMed]
5. Luo, J.; Ok Lee, S.; Liang, L.; Huang, C.K.; Li, L.; Wen, S.; Chang, C. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene 2014, 33, 2768–2778. [CrossRef] [PubMed]
6. Mathivanan, S.; Ji, H.; Simpson, R.J. Exosomes: Extracellular organelles important in intracellular communication. J. Proteom. 2010, 73, 1907–1920. [CrossRef] [PubMed]
7. Qian, Z.; Shen, Q.; Yang, X.; Qiu, Y.; Zhang, W. The role of extracellular vesicles: An epigenetic view of the cancer microenvironment. BioMed Res. Int. 2015, 2015. [CrossRef] [PubMed]
8. Ribatti, D.; Ranieri, G.; Annese, T.; Nico, B. Aquaporins in cancer. Biochim. Biophys. Acta 2014, 1840, 1550–1553. [CrossRef] [PubMed]
9. Zhang, Z.; Chen, Z.; Song, Y.; Zhang, P.; Hu, J.; Bai, C. Expression of aquaporin 5 increases proliferation and metastasis potential of lung cancer. J. Pathol. 2010, 221, 210–220. [CrossRef] [PubMed]
10. Kang, S.K.; Chae, Y.K.; Woo, J.; Kim, M.S.; Park, J.C.; Lee, J.; Soria, J.C.; Jang, S.J.; Sidransky, D.; Moon, C. Role of human aquaporin 5 in colorectal carcinogenesis. Am. J. Pathol. 2008, 173, 518–525. [CrossRef] [PubMed]
11. Yi, F.; Khan, M.; Gao, H.; Hao, F.; Sun, M.; Zhong, L.; Lu, C.; Feng, X.; Ma, T. Increased differentiation capacity of bone marrow-derived mesenchymal stem cells in aquaporin-5 deficiency. Stem Cells Dev. 2012, 21, 2495–2507. [CrossRef] [PubMed]
12. Papadopoulos, M.C.; Saadoun, S.; Verkman, A.S. Aquaporins and cell migration. Eur. J. Physiol. 2008, 456, 693–700. [CrossRef] [PubMed]
13. Verkman, A.S.; Hara-Chikuma, M.; Papadopoulos, M.C. Aquaporins—New players in cancer biology. J. Mol. Med. 2008, 86, 523–529. [CrossRef] [PubMed]
14. Nico, B.; Ribatti, D. Aquaporins in tumor growth and angiogenesis. Cancer Lett. 2010, 294, 135–138. [CrossRef] [PubMed]
15. Hu, J.; Verkman, A.S. Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J. 2006, 20, 1892–1894. [CrossRef] [PubMed]
16. Guo, X.; Sun, T.; Yang, M.; Li, Z.; Li, Z.; Gao, Y. Prognostic value of combined aquaporin 3 and aquaporin 5 overexpression in hepatocellular carcinoma. BioMed Res. Int. 2013, 2013, 206525. [CrossRef] [PubMed]
17. Wu, Z.; Li, S.; Liu, J.; Shi, Y.; Wang, J.; Chen, D.; Luo, L.; Qian, Y.; Huang, X.; Wang, H. RNAi-mediated silencing of AQP1 expression inhibited the proliferation, invasion and tumorigenesis of osteosarcoma cells. *Cancer Biol. Ther.* **2015**, *16*, 1332–1340. [CrossRef] [PubMed]

18. Brooks, H.L.; Regan, J.W.; Yool, A.J. Inhibition of aquaporin-1 water permeability by tetraethylammonium: Involvement of the loop E pore region. *Mol. Pharmacol.* **2000**, *57*, 1021–1026. [PubMed]

19. Wels, J.; Kaplan, R.N.; Rafii, S.; Lyden, D. Migratory neighbors and distant invaders: Tumor-associated niche cells. *Genes Dev.* **2008**, *22*, 559–574. [CrossRef] [PubMed]

20. Jung, Y.; Kim, J.K.; Shiozawa, Y.; Wang, J.; Mishra, A.; Joseph, J.; Berry, J.E.; McGee, S.; Lee, E.; Sun, H.; et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. *Nat. Commun.* **2013**, *4*, 1795. [CrossRef] [PubMed]

21. Bergfeld, S.A.; de Clerck, Y.A. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. *Cancer Metastasis Rev.* **2010**, *29*, 249–261. [CrossRef] [PubMed]

22. Zhang, T.; Lee, Y.W.; Rui, Y.F.; Cheng, T.Y.; Jiang, X.H.; Li, G. Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. *Stem Cell Res. Ther.* **2013**, *13*, 70. [CrossRef] [PubMed]

23. Chaturvedi, P.; Gilkes, D.M.; Wong, C.C.; Kshitzit, L.W.; Zhang, H.; Wei, H.; Takano, N.; Schito, L.; Levcchenko, A.; Semenza, G.L. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. *J. Clin. Investig.* **2013**, *123*, 189–205. [CrossRef] [PubMed]

24. Tu, B.; Du, L.; Fan, Q.M.; Tang, Z.; Tang, T.T. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. *Cancer Lett.* **2012**, *1*, 80–88. [CrossRef] [PubMed]

25. Zannetti, A. A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell secreted PAI-1 on colon cancer cell migration and proliferation. *Biochem. Biophys. Res. Commun.* **2013**, *3*, 1573–1361. [CrossRef] [PubMed]

26. Yu, F.X.; Hu, W.J.; He, B.; Zheng, Y.H.; Zhang, Q.Y.; Chen, L. Bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion. *World J. Surg. Oncol.* **2015**, *15*, 52. [CrossRef] [PubMed]

27. Shinagawa, K.; Kitadai, Y.; Tanaka, M.; Sumida, T.; Kodama, M.; Higashi, Y.; Tanaka, S.; Yasui, W.; Chayama, K. Mesenchymal stem cells enhance growth and metastasis of colon cancer. *Int. J. Cancer* **2010**, *15*, 2323–2333. [CrossRef] [PubMed]

28. Liu, Y.; Han, Z.P.; Zhang, S.S.; Jing, Y.Y.; Bu, X.X.; Wang, C.Y.; Sun, K.; Jiang, G.C.; Zhao, X.; Li, R.; et al. Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. *J. Biol. Chem.* **2011**, *15*, 25007–25015. [CrossRef] [PubMed]

29. Hogan, N.M.; Joyce, M.R.; Murphy, J.M.; Barry, F.P.; O’Brien, T.; Kerin, M.J.; Dwyer, R.M. Impact of mesenchymal stem cell secreted PAI-1 on colon cancer cell migration and proliferation. *Biochem. Biophys. Res. Commun.* **2013**, *13*, 574–579. [CrossRef] [PubMed]

30. Fontanella, R.; Pelagalli, A.; Nardelli, A.; D’Alterio, C.; Ieranò, C.; Cerchia, L.; Lucarelli, E.; Scala, S.; Zannetti, A. A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion. *Cancer Lett.* **2016**, *370*, 100–107. [CrossRef] [PubMed]

31. Clapp, C.; Martínez de la Escalera, G. Aquaporin-1: A novel promote of tumor angiogenesis. *Trends Endocrinol. Metab.* **2006**, *17*, 1–2. [CrossRef] [PubMed]

32. Deetmers, F.J.M.; de Groot, B.L.; Muller, E.M.; Hinton, A.; Konings, I.B.M.; Sze, M.; Flitsch, S.L.; Grubmuller, H.; Deen, P.M.T. Quaternary ammonium compounds as water channel blockers. *J. Biol. Chem.* **2006**, *281*, 14207–14214. [CrossRef] [PubMed]

33. Muller, E.M.; Hub, J.S.; Grubmuller, H.; de Groot, B.L. Is TEA an inhibitor for human Aquaporin-1? *Eur. J. Physiol.* **2008**, *456*, 663–669. [CrossRef] [PubMed]

34. Yang, B.; Kim, J.K.; Verkman, A.S. Comparative efficacy of HgCl2 with candidate aquaporin-1 inhibitors DMSO, gold, TEA+ and acetazolamide. *FEBS Lett.* **2006**, *580*, 6679–6684. [CrossRef] [PubMed]

35. Yamaguchi, T.; Iwata, Y.; Miura, S.; Kawada, K. REinvestigation of drugs and chemicals as aquaporin-1 inhibitors using pressure-induced hemolysis in human erythrocytes. *Biol. Pharm. Bull.* **2012**, *35*, 2088–2091. [CrossRef] [PubMed]

36. Esteva-Font, C.; Jin, B.J.; Phuan, P.W.; Anderson, M.O.; Verkman, A.S. Experimental evaluation of proposed small molecule inhibitors of water channel aquaporin-1. *Mol. Pharmacol.* **2016**, *89*, 686–693. [CrossRef] [PubMed]
37. Dorward, H.S.; Du, A.; Bruhn, M.A.; Wrin, J.; Pei, J.V.; Evdokiou, A.; Price, T.J.; Yool, A.J.; Hardingham, J.E. Pharmacological blockade of aquaporin-1 water channel by AqB013 restricts migration and invasiveness of colon cancer cells and prevents endothelial tube formation in vitro. *J. Exp. Clin. Cancer Res.* **2016**, *35*, 36. [CrossRef] [PubMed]

38. Pierini, M.; Dozza, B.; Lucarelli, E.; Tazzari, P.L.; Ricci, F.; Remondini, D.; di Bella, C.; Giannini, S.; Donati, D. Efficient isolation and enrichment of mesenchymal stem cells from bone marrow. *Cytotherapy* **2012**, *14*, 686–693. [CrossRef] [PubMed]

39. Zannetti, A.; Iommelli, F.; Fonti, R.; Papaccioli, A.; Sommella, J.; Lettieri, A.; Pirozzi, G.; Bianco, R.; Tortora, G.; Salvatore, M.; et al. Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3. *Clin. Cancer Res.* **2008**, *15*, 5209–5219. [CrossRef] [PubMed]

40. Geback, T.; Schulz, M.M.; Koumoutsakos, P.; Detmar, M. TScratch: A novel and simple software tool for automated analysis of monolayer wound healing assays. *Biotechniques* **2009**, *46*, 265–274. [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).